Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma

NCT02575261 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.

NCT NCT02575261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02575261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma
Lead sponsor
Fuda Cancer Hospital, Guangzhou
Phase
Phase 1/2
Overall status
Withdrawn
Start date
September 30, 2015
Completion date
August 15, 2016
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car-t cell immunotherapy, epha2 positive malignant glioma